- Firebrick surged 80pc after launching Nasodine in the US
- Next Science says it antimicrobial solution is effective
Firebrick surges 80pc on Nasodine’s US launch
Firebrick Pharma (ASX:FRE) surged by +80% this morning after announcing that its product, the Nasodine Nasal Spray, is being launched in the US today.
Nasodine will be available to purchase from the company’s US website (nasodine.com), with online promotions commencing this week across the US.
The Nasodine spray claims to help maintain nasal hygiene by eliminating germs, allergens and other airborne threats that disrupt nasal hygiene.
It will be promoted in the US for ‘nasal hygiene’ without any therapeutic claims.
Based on legal advice, this allows Nasodine to be marketed without FDA approval. Since 2020, multiple PVP-I (Povidone-iodine) nasal sprays have been introduced in the US and continue to be marketed this way.
However, the company says Nasodine will be the only PVP-I nasal spray in the US that is supported by demonstrated safety in clinical trials, and a growing list of peer-reviewed publications.
“Our position has always been that if we can make Nasodine available, people will use it,” said Firebrick’s exec chair, Dr Peter Molloy.
“In a post-COVID world, where everyone is concerned about nasal hygiene, we believe Nasodine is the answer.
“Launching Nasodine into the world’s premier pharmaceutical market is a momentous event for our company, culminating more than 10 years of R&D and heralding our transition to a commercial pharmaceutical business,” he added.
Initially, Nasodine will be marketed online only, with an online retail price of US$24.99. In the future, the spray is expected to be available in US pharmacies as well.
Firebrick says it has several other products in development, and expects some of these to become available in the future for the US market.
“We plan to build a portfolio of products under the Nasodine brand and launch them in the US and other markets,” said Dr Molloy.
Next Science says its antimicrobial is effective
Next Science (ASX:NXS) has released preliminary results from two retrospective studies by Dr Ravi K. Bashyal, an orthopaedic surgeon based in Chicago, Illinois.
The studies found XPERIENCE to be efficacious in preventing periprosthetic joint infection in patients undergoing knee and hip arthroplasties (joint replacement).
The XPERIENCE No Rinse Antimicrobial Solution is a surgical irrigation product. It is a clear, colourless solution intended for cleansing and removal of debris, including microorganisms from wounds.
When using XPERIENCE, Dr Bashyal found that the rate of Surgical Site Infection amongst his patients up to 90 days post-surgery has been reduced to zero.
“As Dr Bashyal highlights, infection remains a principal driver of negative outcomes for patients and physicians, and XPERIENCE brings much needed innovation to this area of orthopaedics,” said Next Science’s CEO, I.V. Hall.
“These studies add to the growing body of clinical evidence that increasingly challenge the standard of care in surgical irrigation.
“We will continue to work closely with surgeons to conduct clinical research that demonstrates the effectiveness of our products,” Hall said.
Share prices today: